Top 10 FDA Recalls Physicians Should Know
-
By
-
mdspire news news staff
-
June 18, 2026
-
5 min
By
mdspire news news staff
June 18, 2026
Nirmatrelvir–ritonavir for up to 25 days failed to improve cognitive, autonomic, or exercise symptoms compared with placebo in a phase 2 trial.
September 4, 2026
A protein was linked experimentally to trophoblast invasion.
September 4, 2026
Investigators compared cardiovascular outcomes with tirzepatide and a placebo proxy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
August 28, 2026